10 completed, 1 active not recruiting, 1 terminated. 12 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 10, Active not recruiting 1, Terminated 1 |
| Phase 2 | 5 | Completed 4, Active not recruiting 1 |
Follow Buspirone: new trials by email Literature Review of Buspirone trials Research Report on Buspirone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preventing Gastric Glitch With Prucalopride and Buspirone: N-of-1 Clinical Trial Prucalopride, Buspirone, Placebo - Dyspepsia | Phase 1 / Phase 2 | Completed | Universidade de Passo Fundo | 1 | 2022-01-06 | 2022-05-17 |
| Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES Buspirone, Levodopa-Carbidopa, Buspirone + Levodopa-Carbidopa - Spinal Cord Injuries, Drug Effect | Phase 1 | Completed | Centre Hospitalier Universitaire Vaudois | 3 | 2020-09-11 | 2023-10-05 |
| Buspirone for Opioid Tapering Buspirone oral capsule, Placebo oral capsule - Opioid-Related Disorders, Dependency (Psychology) | Phase 1 | Completed | Johns Hopkins University | 18 | 2018-05-30 | 2020-07-23 |
| Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia Buspirone, Placebo - Parkinson's Disease, Dyskinesias | Phase 1 | Terminated | Oregon Health and Science University | 6 | 2016-01-01 | 2021-03-05 |
| Spinal Cord Neuromodulation for Spinal Cord Injury Epidural Stimulation, Buspirone - Cervical Spinal Cord Injury, Tetraparesis | Phase 1 / Phase 2 | Active not recruiting | University of California, Los Angeles | 12 | 2013-07-01 | 2026-02-13 |
| Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury SPINALON (buspirone + levodopa + cardidopa) - Spinal Cord Injury | Phase 1 / Phase 2 | Completed | Nordic Life Science Pipeline Inc. | 50 | 2013-07-01 | 2015-08-20 |
| Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET Buspirone, Placebo - Smoking Cessation, Tobacco Use Cessation | Phase 1 / Phase 2 | Completed | Centre for Addiction and Mental Health | 6 | 2012-10-01 | 2014-06-04 |
| Early Pharmacotherapy Aimed at Neuroplasticity in Autism : Safety and Efficacy Buspirone - Autism | Phase 1 / Phase 2 | Completed | Chugani, Diane C. | 20 | 2004-03-01 | 2011-07-20 |
| Buspirone Hydrochloride 30mg Tablets, Fasting BUSPAR® 30 mg Tablet, Buspirone Hydrochloride 30 mg Tablet - Healthy | Phase 1 | Completed | Teva Pharmaceuticals USA | 70 | 2001-12-01 | 2024-08-19 |
| Buspirone Hydrochloride 30mg Tablets, Non-Fasting BUSPAR® 30 mg Tablet, Buspirone Hydrochloride 30 mg Tablet - Healthy | Phase 1 | Completed | Teva Pharmaceuticals USA | 24 | 2001-12-01 | 2024-08-19 |
| Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed Conditions Buspirone HCl, Buspar - To Determine Bioequivalence Under Fed Conditions | Phase 1 | Completed | Par Pharmaceutical, Inc. | 21 | 1998-07-01 | 2017-09-26 |
| Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions buspirone HCl, Buspar - To Determine Bioequivalence Under Fasting Conditions | Phase 1 | Completed | Par Pharmaceutical, Inc. | 48 | 1998-06-01 | 2008-04-04 |
Quadriplegia (2) · Spinal Cord Injuries (2) · Autistic Disorder (1) · Chronic Pain (1) · Dyskinesias (1) · Dyspepsia (1) · Fasting (1) · Lecithin Cholesterol Acyltransferase Deficiency (1) · Movement Disorders (1) · Opioid-Related Disorders (1) · Paraplegia (1) · Parkinson Disease (1) · Smoking Cessation (1) · Tobacco Use Cessation (1)
Par Pharmaceutical, Inc. (2) · Teva Pharmaceuticals USA (2) · Centre Hospitalier Universitaire Vaudois (1) · Centre for Addiction and Mental Health (1) · Chugani, Diane C. (1) · Johns Hopkins University (1) · Nordic Life Science Pipeline Inc. (1) · Oregon Health and Science University (1) · Universidade de Passo Fundo (1) · University of California, Los Angeles (1)
United States (6) · Canada (4) · Brazil (1) · Switzerland (1)
James D. Carlson, Pharm.D. (2) · Bernard Le Foll, MD, PhD (1) · Daniel C Lu, MD PhD (1) · Fernando Fornari (1) · Isabelle Boileau, PhD (1) · Jocelyne Bloch, Pr MD (1) · Mohan Radhakrishna, MD (1) · Pierre Guertin, Ph.D. (1) · Samuel Serfaty, MD (1) · Samuel Surfaty, MD (1)
2019 (1)